Introduction:
The global market for biosimilars in the advanced therapy medicinal products (ATMP) sector is rapidly expanding, with various countries implementing regulations to ensure the safety and efficacy of these products. In 2026, the top 20 leading biosimilars ATMP regulations worldwide are crucial for pharmaceutical companies to understand in order to navigate the complex regulatory landscape and expand their market presence. According to industry reports, the global biosimilars market is projected to reach $69.5 billion by 2026.
Top 20 Leading Biosimilars ATMP Regulations Worldwide 2026:
1. United States
– The US FDA remains a key regulatory authority in the biosimilars ATMP sector, with over 25 approved biosimilars on the market.
– The US market for biosimilars is expected to reach $19.5 billion by 2026.
2. European Union
– The European Medicines Agency (EMA) plays a crucial role in regulating biosimilars in the EU, with rigorous guidelines for approval.
– The EU biosimilars market is projected to grow at a CAGR of 25% from 2021 to 2026.
3. Japan
– The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved several biosimilars, with a focus on increasing access to affordable biologics.
– Japan is expected to be the second-largest market for biosimilars by 2026.
4. South Korea
– The Ministry of Food and Drug Safety (MFDS) in South Korea has implemented regulations to streamline the approval process for biosimilars.
– South Korea is a key player in the biosimilars market, with several domestic companies leading in the development and production of biosimilars.
5. India
– The Central Drugs Standard Control Organization (CDSCO) in India has established guidelines for the approval and marketing of biosimilars.
– India is a major player in the global biosimilars market, with a growing number of companies investing in biosimilar development.
6. China
– The National Medical Products Administration (NMPA) in China has been actively promoting the development and approval of biosimilars.
– China is projected to be a key market for biosimilars, with a growing demand for affordable biologics.
7. Brazil
– The National Health Surveillance Agency (ANVISA) in Brazil has implemented regulations to ensure the quality and safety of biosimilars.
– Brazil is a growing market for biosimilars, with increasing access to biologic therapies for patients.
8. Russia
– The Federal Service for Surveillance in Healthcare (Roszdravnadzor) in Russia regulates the approval and marketing of biosimilars.
– Russia is a key player in the biosimilars market, with several domestic companies leading in the production of biosimilars.
9. Australia
– The Therapeutic Goods Administration (TGA) in Australia has established guidelines for the approval and registration of biosimilars.
– Australia is a growing market for biosimilars, with increasing adoption of these products in the healthcare system.
10. Canada
– Health Canada regulates the approval and marketing of biosimilars in Canada, with a focus on increasing access to affordable biologics.
– Canada is projected to be a key market for biosimilars, with a growing number of approved products in the market.
11. Mexico
– The Federal Commission for Protection against Sanitary Risk (COFEPRIS) in Mexico oversees the approval and marketing of biosimilars.
– Mexico is a growing market for biosimilars, with increasing demand for affordable biologic therapies.
12. Argentina
– The National Administration of Drugs, Food and Medical Technology (ANMAT) in Argentina regulates the approval and marketing of biosimilars.
– Argentina is a key player in the biosimilars market in Latin America, with a growing number of approved products.
13. South Africa
– The South African Health Products Regulatory Authority (SAHPRA) in South Africa has established guidelines for the approval and registration of biosimilars.
– South Africa is a growing market for biosimilars, with increasing access to these products in the healthcare system.
14. Turkey
– The Turkish Medicines and Medical Devices Agency (TITCK) in Turkey regulates the approval and marketing of biosimilars.
– Turkey is a key player in the biosimilars market in the Middle East and North Africa region, with a growing number of approved products.
15. Saudi Arabia
– The Saudi Food and Drug Authority (SFDA) in Saudi Arabia oversees the approval and marketing of biosimilars.
– Saudi Arabia is a growing market for biosimilars, with increasing adoption of these products in the healthcare system.
16. UAE
– The Ministry of Health and Prevention (MOHAP) in the UAE regulates the approval and marketing of biosimilars.
– The UAE is a key player in the biosimilars market in the Middle East region, with a growing number of approved products.
17. Israel
– The Ministry of Health in Israel regulates the approval and marketing of biosimilars.
– Israel is a growing market for biosimilars, with increasing access to affordable biologic therapies.
18. Singapore
– The Health Sciences Authority (HSA) in Singapore has established guidelines for the approval and registration of biosimilars.
– Singapore is a key player in the biosimilars market in Asia, with a growing number of approved products.
19. Malaysia
– The National Pharmaceutical Regulatory Agency (NPRA) in Malaysia regulates the approval and marketing of biosimilars.
– Malaysia is a growing market for biosimilars, with increasing demand for affordable biologic therapies.
20. Thailand
– The Food and Drug Administration (FDA) in Thailand oversees the approval and marketing of biosimilars.
– Thailand is a growing market for biosimilars, with increasing adoption of these products in the healthcare system.
Insights:
The global biosimilars market is expected to continue its rapid growth, driven by increasing demand for affordable biologic therapies and the implementation of regulations to streamline the approval process for biosimilars. By 2026, the market is projected to reach $69.5 billion, with key regions such as the US, EU, Japan, and South Korea leading the way. Pharmaceutical companies should closely monitor the top 20 leading biosimilars ATMP regulations worldwide to capitalize on the opportunities presented by this expanding market.
Related Analysis: View Previous Industry Report
